News : 2017 : August

Schiff Center hosts Hepatobiliary Disease in Clinical Practice Update XXII

Over 100 physicians and medical professionals from around the country gathered at the InterContinental Miami in Miami, Florida for the bi-annual Hepatobiliary Disease in Clinical Practice Update:XXII presented by the Schiff Center for Liver Diseases. The two day course served as an update of knowledge in the diagnosis and management of liver and biliary disease. Course director Dr. Eugene Schiff selected national and international experts to share their groundbreaking research so that the most up-to-date information would be presented and discussed.

The scope of the course was comprehensive, encompassing a spectrum of emerging therapies for NASH, evaluating the difficulty of eradicating HCV globally, evaluating the spectrum of antifibrotic targets, reviewing a potential cure for Alpha-1 Antitrypsin Deficiency, assessing the prevalence of unrecognized Alcoholic Liver Diseases, identifying the basis for new treatment targets against HCC, understanding the mechanisms of new therapies for PBC and PSC, and other relevant topics in Hepatology. These topics were presented by professors from leading research institutions across the country who have dedicated years of study to researching their areas of interest.

To demonstrate the applications of the newest research, the course lecturers participated in a panel in which they analyzed real case studies on patients seen at the Schiff Center for Liver Diseases presented by Schiff Center and Division of Hepatology research coordinators, nurses, and research fellows. The course faculty gave their input on treatment, diagnosis and management of the case study patient and engaged in lively discussion moderated by Dr. Schiff.

In all, the Hepatobiliary Disease in Clinical Practice Update:XXII was a tremendous effort by the University of Miami Miller School of Medicine that united medical professionals for the ultimate goal of providing the most up to date information about hepatobiliary diseases and providing the opportunity to connect with hepatology’s leaders from around the nation. With experiments on novel therapies for NASH, finite treatments for HBV, and new treatment targets for HCC, there will undoubtedly be plenty of new research and studies in the coming two years that will be featured in the next Hepatobiliary Disease in Clinical Practice Update.